Dysport abobotulinumtoxinA: Additional Phase III data

Additional data from a double-blind, international Phase III trial in 241 children ages 2-17 with dynamic equinus foot deformity due to cerebral palsy showed that the 15 U/kg/leg dose of Dysport signi...